For Immediate Release
March 22, 2011
SEATTLE CANCER CARE ALLIANCE AND PROCURE BREAK GROUND ON
NORTHWEST’S FIRST PROTON THERAPY CENTER TO TREAT CANCER
SEATTLE – The Seattle Cancer Care Alliance, together with ProCure Treatment Centers Inc., today held its ceremonial groundbreaking on a new proton therapy center in north Seattle that will provide a first-of-its-kind treatment option for cancer patients throughout the Northwest.
When it opens in early 2013 on the campus of Northwest Hospital & Medical Center, the 60,000-square-foot facility will be among only a handful of centers in the nation to offer proton therapy.
Proton therapy is an advanced form of radiation treatment and an important alternative to standard X-ray radiation for many types of cancer and some non-cancerous tumors. Currently available at only nine centers in the United States, proton therapy is beneficial in treating a broad range of tumors, including those of the brain, central nervous system, gastrointestinal tract, head and neck, lung and prostate, as well as sarcomas and many pediatric cancers.
While proton and X-ray therapy both kill cancer cells by preventing them from dividing and growing, the difference between the two is that protons can be controlled more precisely than X-rays. Proton beams deposit the greatest amount of radiation right into the tumor and then stop, which allows patients to receive higher doses with less damage to nearby healthy tissue. In contrast, X-ray radiation releases substantial doses of energy quickly after penetrating the skin, which can damage healthy tissue and organs on the way to the tumor.
The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors, such as those at the base of the skull and along the spinal cord. Patients who receive proton therapy generally experience fewer side effects compared to those who undergo traditional X-ray-based radiation therapy.
Since children’s bodies are still growing, children are more sensitive to damage to healthy tissue caused by radiation. They can experience more serious short- and long-term side effects from X-ray radiation. Studies show that using proton therapy to treat pediatric tumors provides excellent results in controlling tumors, reducing damage to healthy tissue, and lowering risks of tumors returning later in life.
“The SCCA was formed to accelerate the development and evaluation of new therapies for cancer, and in turn make those therapies more widely available in our region,” said Norm Hubbard, executive vice president of the SCCA. “Proton therapy has emerged as a compelling treatment for adults and children with cancer and other tumors. Prior to the development of this center, patients would have to travel hundreds of miles to receive this precise, live-saving treatment. It’s also fitting that this groundbreaking launches the SCCA’s second decade of treating patients from the Northwest and beyond.”
Like other clinical programs at the SCCA, the proton center is expected to attract patients nationally and internationally. SCCA Proton Therapy, A ProCure Center expects to treat about 1,400 proton therapy patients annually.
“As satisfying as today is, the real reward is going to come when the doors open to treat patients and the Pacific Northwest has its first proton therapy center,” said John Henderson, chief operating officer of ProCure, an organization based in Bloomington, Ind., which in 2009 formed a joint venture with the SCCA.
“ProCure brings expertise in proton therapy through its experienced management team, its ability to leverage scale in purchasing and operations, as well as its substantial investment in training for physicians and therapists. This experience and expertise significantly decreases the overall cost and risk of the project to the SCCA,” Hubbard said.
The SCCA will provide clinical leadership as well as operational integration into its comprehensive cancer services. Physicians will be able to lead research efforts to determine the best application of this developing technology.
"Proton radiotherapy is the most precise form of radiotherapy available today and will improve the outcomes for a large number of cancer patients,” said George Laramore, Ph.D., M.D, chair of the Department of Radiation Oncology at the University of Washington and medical director of SCCA Proton Therapy, A ProCure Center.
The Seattle facility is the fourth in the ProCure network, which includes centers in Oklahoma City (opened in 2009), suburban Chicago (opened in 2010) and Somerset, N.J., which serves the metro New York area (opening 2012). ProCure is the only healthcare company in the world that has developed and is operating multiple proton centers.
SCCA and ProCure chose to build the Center at Northwest Hospital because of the hospital’s history of building health care partnerships to provide emerging and innovative treatments to its community, and because the center will be conveniently located near other cancer services and complementary facilities on the hospital campus.
The new facility will create approximately 100 full-time jobs and 400 temporary positions for construction and start-up operations. Washington-based contractors will be used to construct the facility.
Federal support and private grants, including one from Seattle’s Norcliffe Foundation, contributed to the financing of the proton center. To learn more about proton therapy and the Center, visit www.procure.com/wa
# # #
SEATTLE CANCER CARE ALLIANCE – 10 YEARS, THOUSANDS OF LIVES SAVED
Every day, the goal of Seattle Cancer Care Alliance is to turn cancer patients into cancer survivors. SCCA unites the adult and pediatric cancer-care programs of Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children’s. Together they comprise the only National Cancer Institute-designated comprehensive cancer center in six states, from Washington to the Dakotas. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside. Patients receive the latest research-based cancer therapies as well as cutting-edge treatments. SCCA has three clinical-care sites: an outpatient clinic on the Hutchinson Center campus, a pediatric-inpatient unit at Children’s and an adult-inpatient unit at UW Medical Center. SCCA celebrates its 10th anniversary in 2011. For more information, visit www.seattlecca.org
PROCURE TREATMENT CENTERS, INC.
ProCure Treatment Centers, Inc. is a privately held health care company dedicated to improving the lives of patients with cancer by increasing access to proton therapy. The company was founded in 2005 in Bloomington, Ind., and is the first to develop a network of proton therapy centers in cities across the United States. The ProCure Proton Therapy Center in Oklahoma City opened in July 2009 and the CDH Proton Center, A ProCure Center, opened October 2010 in Warrenville, Ill. ProCure’s third and fourth centers are under construction in Somerset, N.J. and Seattle; and others are in development in Detroit and South Florida. ProCure provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of proton therapy centers. ProCure’s solution reduces the time, cost and effort necessary to build and operate a facility. ProCure is advancing proton therapy by collaborating with radiation oncology practices and hospitals to develop centers, through innovation and improvements in technology, and by providing training at the world’s only educational facility specializing in proton therapy. For more information, visit www.procure.com.
Dean Forbes (for SCCA)
Danielle Zarella, Richmond Public Relations (for ProCure)